Enoxaparin
ApprovedUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Thromboembolism
Conditions
Thromboembolism
Trial Timeline
Nov 1, 2006 → Dec 1, 2012
NCT ID
NCT00444652About Enoxaparin
Enoxaparin is a approved stage product being developed by Sanofi for Thromboembolism. The current trial status is unknown. This product is registered under clinical trial identifier NCT00444652. Target conditions include Thromboembolism.
What happened to similar drugs?
5 of 20 similar drugs in Thromboembolism were approved
Approved (5) Terminated (4) Active (13)
Hype Score Breakdown
Clinical
20
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04492254 | Phase 3 | Terminated |
| NCT00908960 | Phase 2 | Completed |
| NCT00518245 | Approved | Terminated |
| NCT00622115 | Phase 1 | Completed |
| NCT00723216 | Phase 3 | Completed |
| NCT00444652 | Approved | UNKNOWN |
| NCT00769873 | Phase 2 | Terminated |
| NCT00413374 | Pre-clinical | Completed |
| NCT00265993 | Approved | Completed |
| NCT00043784 | Phase 3 | Completed |
| NCT00289042 | Approved | Completed |
Competing Products
20 competing products in Thromboembolism